Reuters logo
in 10 months
BRIEF-Ab Science announces update on masitinib
September 29, 2016 / 3:51 PM / in 10 months

BRIEF-Ab Science announces update on masitinib

1 Min Read

Sept 29 (Reuters) - Ab Science Sa :

* Announces the filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European medicines agency

* Masitinib also received from european medicines agency (EMA) committee for orphan medicinal products (comp) orphan drug designation

* FDA approved first compassionate use of masitinib in amyotrophic lateral sclerosis

* EMA decision on registering masitinib in ALS should be known during second half of 2017

* Review process started on 12 September 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below